Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
$3.96
-3.6%
$4.24
$1.00
$5.87
$35.13M0.71144,190 shs7,275 shs
LianBio stock logo
LIAN
LianBio
$0.42
-4.0%
$0.34
$0.27
$4.99
$44.95M0.231.04 million shs32,698 shs
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
$1.22
-11.6%
$1.06
$0.87
$8.60
$9.12M0.5885,047 shs353,064 shs
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$3.18
+8.0%
$1.94
$0.51
$3.19
$177.29M1.331.21 million shs621,500 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
+6.20%+0.61%-13.11%+48.91%+129.48%
LianBio stock logo
LIAN
LianBio
-3.99%-2.07%+12.07%+108.00%+34.19%
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
+39.25%+30.81%+38.00%-20.00%+137,999,900.00%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
+1.38%+1.38%+17.60%+398.39%+131.50%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
2.6285 of 5 stars
3.35.00.00.00.01.70.0
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/AN/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.3481 of 5 stars
0.03.00.00.00.60.80.6
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
3.8818 of 5 stars
3.35.00.04.70.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
2.50
Moderate Buy$12.00203.03% Upside
LianBio stock logo
LIAN
LianBio
0.00
N/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
0.00
N/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
2.50
Moderate Buy$5.0057.48% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/A$1.04 per shareN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/A$2.71 per shareN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
$80.82MN/AN/AN/A$8.86 per shareN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$47.98M3.70N/AN/A$0.85 per share3.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
-$12.54MN/A0.00N/AN/AN/AN/A8/4/2025 (Estimated)
LianBio stock logo
LIAN
LianBio
-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
-$61.09MN/A0.00N/AN/AN/AN/A8/21/2025 (Estimated)
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$68.57M-$1.28N/AN/AN/A-156.48%-123.50%-58.96%8/4/2025 (Estimated)

Latest LSB, LIAN, SPRO, and ATHE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.35N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/AN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/A
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
N/AN/AN/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/A
3.84
N/A
LianBio stock logo
LIAN
LianBio
N/A
10.06
10.06
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
N/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/A
2.56
2.56

Institutional Ownership

CompanyInstitutional Ownership
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
2.14%
LianBio stock logo
LIAN
LianBio
74.85%
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
52.64%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
25.60%

Insider Ownership

CompanyInsider Ownership
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
38.80%
LianBio stock logo
LIAN
LianBio
7.59%
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
N/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
5.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
108.87 million5.43 millionNot Optionable
LianBio stock logo
LIAN
LianBio
110108.06 million99.86 millionNot Optionable
LakeShore Biopharma Co., Ltd. stock logo
LSB
LakeShore Biopharma
773N/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
15055.91 million52.84 millionOptionable

Recent News About These Companies

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alterity Therapeutics stock logo

Alterity Therapeutics NASDAQ:ATHE

$3.96 -0.15 (-3.65%)
As of 12:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

LianBio stock logo

LianBio NASDAQ:LIAN

$0.42 -0.02 (-3.99%)
As of 07/7/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

LakeShore Biopharma stock logo

LakeShore Biopharma NASDAQ:LSB

$1.22 -0.16 (-11.59%)
As of 12:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

Spero Therapeutics stock logo

Spero Therapeutics NASDAQ:SPRO

$3.18 +0.24 (+7.99%)
As of 12:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.